

SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092
E-mail : compliance@sudarshanpharma.com Website : www.sudarshanpharma.com
Board Line : + 91-22-42221111 / 42221116 (100 line) CIN : L51496MH2008PLC184997

SPIL/CS/SE/2024-2025/37

Date: 14th October 2024

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01015

Sub: Intimation for acquisition of the shares of Ishwari Healthcare Private Limited
Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), this is to inform you that the Board of Directors of the Company have, on 14th October, 2024 inter-alia approved to acquire 2,09,100 equity shares of Rs.10/- each of Ishwari Healthcare Private Limited ('Ishwari Healthcare') (CIN: U85100MH2011PTC212867) equivalent to 51.00% of the paid up equity share capital of the Company and enter into Share Purchase Agreement. Upon completion of the acquisition, Ishwari Healthcare would become a subsidiary of the Company.

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given in Annexure A.

This is for your information and record.

Thanks & Regards,

Yours faithfully,

For, Sudarshan Pharma Industries Limited

Hemal Mehta
Chairman & Managing Director





SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises.7, S.V.Road Boriwali (west) Mumbai - 400092


E-mail : compliance@sudarshanpharma.com Website : www.sudarshanpharma.com

Board Line : + 91-22-42221111 / 42221116 (100 line) CIN : L51496MH2008PLC184997

Annexure-A.

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are given below:

SL NO	Details to be Provided	Information
1	Name of the target entity, details in brief such as size, etc.	Name: Ishwari Healthcare Private Limited (As on 31 st March 2024) Authorised Share Capital: Rs.50,00,000/- Paid Up Share Capital: Rs.41,00,000/- Total Income: Rs.3,72,00,800/-
2	Whether the acquisition would fall within related party transactions and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of the interest and details thereof and whether the same is done at 'arm's length'	No. The acquisition would not fall within the related party transactions.
3	Industry to which the entity being acquired belongs.	Ishwari Healthcare Private Limited is in the business to produce, process, prepare, treat, disinfect, compound, formulate, mix, concentrate, pack, repack, refine, add, remove, pure, preserve, grade, freeze, distillate, boil, sterilize, improve, extract, buy, sell, resell, trade, import, export, barter, transport, store, forward, distribute, dispose, develop, research, discover, manipulate, market, supply and to act as agent, broker, adatia, representative, consultant, collaborator, stockist, liasioner, middleman, jobworker or otherwise to deal in all types of medical and surgical instruments and equipments goods, products, instruments, apparatus, and devices relating to all branches of medicine, surgery and healthcare including cardiology, ophthalmology and neurology, descriptions, specifications, strengths and applications of pharmaceutical, chemical and healthcare products of medicaments in all its branches such as allopathic, ayurvedic, homeopathic, herbal, unani, siddha, bio-chemi, naturopathy etc., used for treatment, cure and healthcare of human beings and animals and other allied goods and to do trading business by way of becoming manufacturers, buyers, sellers, importers, exporters, distributors, stockists, retailers, wholesalers, consignors, consignees agents, dealers, distributors, stockist, etc.





SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises,7, S.V.Road Boriwali (west) Mumbai - 400092

E-mail : compliance@sudarshanpharma.com Website : www.sudarshanpharma.com

Board Line : + 91-22-42221111 / 42221116 (100 line) CIN : L51496MH2008PLC184997

		provider, handling and haulage contractors, handling goods, Warehousemen, Transport Agents and contractors for healthcare product companies.								
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Ishwari Healthcare Private Limited has a similar line of business of dealing in all types of medical, surgical instruments, equipment, goods, products, instruments, apparatus and devices relating to all branches of medicine, surgery and healthcare.								
5	Brief details of governmental or any regulatory approvals "required for the acquisition	Not Applicable								
6	Indicative time period for completion of the acquisition	31 st October, 2024								
7	Nature of Consideration whether Cash consideration or share swap and details of the same	To be subscribed in cash.								
8	Cost of acquisition or the price at which the shares are acquired.	Rs.2,60,00,000/- only (Rupees Two Crores and Sixty Lakhs only)								
9	Percentage of shareholding control acquired and /or number of shares acquired	2,09,100 equity shares of Rs.10/- each (51.00% of the paid-up share capital) of Ishwari Healthcare Private Limited.								
10	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p><u>Brief background:</u></p> <p>Ishwari Healthcare Private limited was incorporated on 31st January 2011.</p> <p>Ishwari Healthcare Private limited is a progressive & innovative Company dedicated to serve world market by providing superior services, user-friendly and state-of-the-art healthcare disposables & devices conforming to international standards at competitive prices. Putting technology to the best use combined with the spirit of innovativeness and creativity, Ishwari Healthcare Private limited provides world-class products to cater the needs of global customers more effectively and efficiently.</p> <p>Last 3 years' turnover details:</p> <table><thead><tr><th>Financial Year</th><th>(Amount in Lakhs)</th></tr></thead><tbody><tr><td>2023-2024</td><td>372.00</td></tr><tr><td>2022-2023</td><td>524.24</td></tr><tr><td>2021-2022</td><td>625.92</td></tr></tbody></table>	Financial Year	(Amount in Lakhs)	2023-2024	372.00	2022-2023	524.24	2021-2022	625.92
Financial Year	(Amount in Lakhs)									
2023-2024	372.00									
2022-2023	524.24									
2021-2022	625.92									





SUDARSHAN PHARMA INDUSTRIES LTD

Head office : 301.Aura Biplax, Premium Retail, Premises,7, S.V.Road Borivali (west) Mumbai - 400092
E-mail : compliance@sudarshanpharma.com Website : www.sudarshanpharma.com
Board Line : + 91-22-42221111 / 42221116 (100 line) CIN : L51496MH2008PLC184997

Countries in which the acquired entity has presence: India, Nigeria, Benin, Sudan, Yemen, Zambia, Myanmar.

For, Sudarshan Pharma Industries Limited

Hemal Mehta
Chairman & Managing Director

